Suzanne Y.
- Country
- The Netherlands
- Department
- Afdeling Oogheelkunde
Research Overview
- NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa
- Long-Term Safety and Efficacy Assessment of Botaretigene Sparoparvovec in X-Linked Retinitis Pigmentosa with RPGR Gene Variants
- Evaluation of Prednisolone Acetate and Placebo Eye Drops in Patients with Chronic Central Serous Chorioretinopathy
Data & Insights
Has run more than one trial at 10 of 18 partner sites.
Specializations
Retinal Degenerative Disorders
This investigator specializes in treating inherited retinal diseases, with particular emphasis on retinitis pigmentosa. Their research encompasses both traditional and innovative therapeutic approaches for managing progressive vision loss.
- N-acetylcysteine therapy
- USH2A gene-related treatments
The investigator focuses on maintaining visual function and reducing visual disability through targeted interventions.
Rare Genetic Eye Conditions
Expertise extends to treating Leber congenital amaurosis, particularly cases involving CEP290 gene mutations. The investigator works with novel therapeutic approaches for addressing these challenging genetic conditions.
- Sepofarsen treatment evaluation
- Gene-targeted therapies
Their work aims to develop effective treatments for previously untreatable inherited eye disorders.
Retinal Fluid Disorders
The investigator has significant experience in treating central serous chorioretinopathy, focusing on managing chronic cases through various therapeutic interventions.
- Topical steroid treatments
- Retinal fluid management
Their research emphasizes the evaluation of subretinal and intraretinal fluid using advanced imaging techniques.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.